ENGOT-ov51/NItCHE/MITO33

Randomized phase III trial on NIraparib-dostarlimab vs physiscian’s choice CHEmotherapy in recurrent, platinum resistant ovarian, fallopian tube or primary peritoneal cancer

Contact Person
Status
Recruiting
Disease Site
Ovarian
Lead Cooperative Group
Participating Groups
MaNGO
GINECO
NOGGO
CEEGOG
GCIG Number